Abnormal Food-Seeking Behavior after Surgery for Craniopharyngioma

Skórzewska, Anna; Lal, Samarthji; Waserman, Jack; Guyda, H.

doi:10.1159/000118545

Cited by 45 publications

(29 citation statements)

References 10 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The weight gain appears to be unrelenting. 1,5,8,9,12 One of 2 patients described by Costin et al 4 continued to demonstrate weight gain of more than 7 kg/y for up to 4 years postoperatively. In a series of 21 patients, Curtis et al 3 noted significant weight gain 3 years postoperatively.…”

Section: Commentmentioning

confidence: 99%

The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma

Mason¹,

Krawiecki²,

Meacham³

2002

Arch Pediatr Adolesc Med

129

102

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 99%

The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma

Mason¹,

Krawiecki²,

Meacham³

2002

Arch Pediatr Adolesc Med

129

102

View full text Add to dashboard Cite

show abstract

“…After resection of craniopharyngiomas, children will lose their ability to downregulate appetite, demonstrate abnormal food-seeking behavior, and rapidly gain weight. 2,3,6,7,51,52 This can result in daytime somnolence either directly 20 or secondary to OSA. 14,15,19 Our observation that in the 2 morbidly obese patients MSLT scores did not change significantly on documented optimal CPAP treatment suggests that their sleepiness was not caused by sleep-disordered breathing.…”

Section: Figmentioning

confidence: 99%

Severe Hypersomnolence After Pituitary/Hypothalamic Surgery in Adolescents: Clinical Characteristics and Potential Mechanisms

Snow¹,

Gozal

Malhotra

et al. 2002

Pediatrics

View full text Add to dashboard Cite

ABSTRACT. Objectives. After resection of hypothalamic/pituitary tumors, children are at risk for development of hormonal deficiencies, obesity, and hypersomnolence. However, the prevalence and pathophysiology of these complications are unclear. The purpose of this study was to assess the prevalence and severity of hypersomnolence in children after resection of pituitary tumors and to study the potential factors that contribute to this sleepiness if present. We further hypothesized that decrements in orexin levels may contribute to the sleepiness.Methods. Six children who underwent hypothalamic/ pituitary surgery were identified. Five of these patients and 5 matched control subjects underwent overnight polysomnography followed by a multiple sleep latency test. Children who had a primary sleep disorder (eg, obstructive sleep apnea) underwent treatment and were restudied subsequently (n ‫؍‬ 2). Blood levels of pituitary hormones were measured. Blood and cerebrospinal fluid (CSF) were drawn from 4 patients and 3 control subjects to measure orexin levels.Results. Endocrine control was appropriate in all children. Although patients had longer sleep duration but similar sleep efficiency than control subjects, relatively severe daytime somnolence was present (mean sleep latency: 10.3 ؎ 5.3 minutes vs 26.2 ؎ 1.1 minute in control subjects). Sleepiness did not correlate with body mass index or age. Furthermore, serum and CSF orexin levels did not differ between patients and control subjects.Conclusions. Severe daytime sleepiness is frequent among children who undergo pituitary/hypothalamic surgery and does not seem to result from inappropriate cortisol or thyroxine replacement, disturbed nocturnal sleep, or low levels of orexin in the serum or CSF. We therefore speculate that other, unidentified neurohormonal mechanisms may mediate the excessive sleepiness of these patients. Pediatrics 2002;110(6). URL: http:// www.pediatrics.org/cgi/content/full/110/6/e74; sleep, excessive daytime sleepiness, adolescents, orexin (hypocretin), brain tumors, craniopharyngioma.

show abstract

“…CD133 is a marker of self-renewing hematopoietic (19) and neural (20) stem cells that also identifies TIC populations in multiple human cancers (3)(4)(5)(6). CD133 expression correlates with disease progression, metastasis, recurrence, and poor overall survival in several human malignancies (21,22), but insight into its function remains limited (23,24).…”

Section: Introductionmentioning

confidence: 99%

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells

Venugopal

Hallett

Vora

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Clonal evolution of cancer may be regulated by determinants of stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties of stemness affect such functional processes. Glioblastoma-initiating cells (GICs), identified by expression of the cell surface marker CD133, are shown to be chemoradioresistant. In the current study, we sought to elucidate the functional role of CD133 in self-renewal and identify compounds that can specifically target this CD133 þ treatment-refractory population.Experimental Design: Using gain/loss-of-function studies for CD133 we assessed the in vitro self-renewal and in vivo tumor formation capabilities of patient-derived glioblastoma cells. We generated a CD133 signature combined with an in silico screen to find compounds that target GICs. Self-renewal and proliferation assays on CD133-sorted samples were performed to identify the preferential action of hit compounds. In vivo efficacy of the lead compound pyrvinium was assessed in intracranial GIC xenografts and survival studies. Lastly, microarray analysis was performed on pyrvinium-treated GICs to discover core signaling events involved.Results: We discovered pyrvinium, a small-molecule inhibitor of GIC self-renewal in vitro and in vivo, in part through inhibition of Wnt/b-catenin signaling and other essential stem cell regulatory pathways. We provide a therapeutically tractable strategy to target self-renewing, chemoradioresistant, and functionally important CD133 þ stem cells that drive glioblastoma relapse and mortality. Conclusions:Our study provides an integrated approach for the eradication of clonal populations responsible for cancer progression, and may apply to other aggressive and heterogeneous cancers.

show abstract

Abnormal Food-Seeking Behavior after Surgery for Craniopharyngioma

Cited by 45 publications

References 10 publications

The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma

The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma

Severe Hypersomnolence After Pituitary/Hypothalamic Surgery in Adolescents: Clinical Characteristics and Potential Mechanisms

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells

Contact Info

Product

Resources

About